[go: up one dir, main page]

CY1123831T1 - Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων - Google Patents

Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων

Info

Publication number
CY1123831T1
CY1123831T1 CY20211100142T CY211100142T CY1123831T1 CY 1123831 T1 CY1123831 T1 CY 1123831T1 CY 20211100142 T CY20211100142 T CY 20211100142T CY 211100142 T CY211100142 T CY 211100142T CY 1123831 T1 CY1123831 T1 CY 1123831T1
Authority
CY
Cyprus
Prior art keywords
genetically modified
cell receptors
modified mouse
human animal
creating
Prior art date
Application number
CY20211100142T
Other languages
English (en)
Inventor
Lynn Macdonald
Andrew J. Murphy
John Mcwhirter
Naxin Tu
Vera VORONINA
Cagan Gurer
Karolina MEAGHER
Sean Stevens
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1123831T1 publication Critical patent/CY1123831T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση παρέχει ένα γενετικώς τροποποιημένο μη-ανθρώπινο ζώο το οποίο περιλαμβάνει στο γονιδίωμα του μη-αναδιατεταγμένους μεταβλητούς γονιδιακούς τόπους υποδοχέα Τ κυττάρων, καθώς επίσης μη-ανθρώπινα έμβρυα, κύτταρα και ιστούς που τους περιλαμβάνουν. Παρέχονται επίσης κατασκευάσματα για δημιουργία του εν λόγω γενετικώς τροποποιημένου μη-ανθρώπινου ζώου και μέθοδοι δημιουργίας τους. Διάφορες μέθοδοι χρήσης του γενετικώς τροποποιημένου μη-ανθρώπινου ζώου επίσης παρέχονται.
CY20211100142T 2011-10-28 2021-02-19 Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων CY1123831T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161552582P 2011-10-28 2011-10-28
US201261621198P 2012-04-06 2012-04-06
US201261700908P 2012-09-14 2012-09-14
PCT/US2012/062065 WO2013063361A1 (en) 2011-10-28 2012-10-26 Genetically modified t cell receptor mice
EP12784833.1A EP2771357B1 (en) 2011-10-28 2012-10-26 Genetically modified t cell receptor mice

Publications (1)

Publication Number Publication Date
CY1123831T1 true CY1123831T1 (el) 2022-05-27

Family

ID=47178340

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101057T CY1120945T1 (el) 2011-10-28 2018-10-16 Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων
CY20211100142T CY1123831T1 (el) 2011-10-28 2021-02-19 Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY181101057T CY1120945T1 (el) 2011-10-28 2018-10-16 Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων

Country Status (25)

Country Link
US (4) US9113616B2 (el)
EP (3) EP3795587A1 (el)
JP (7) JP6254528B2 (el)
KR (5) KR102321909B1 (el)
CN (5) CN114891798B (el)
AU (5) AU2012327204B2 (el)
BR (1) BR112014009203B1 (el)
CA (1) CA2853707A1 (el)
CY (2) CY1120945T1 (el)
DK (2) DK2771357T3 (el)
ES (2) ES2858978T3 (el)
HR (2) HRP20181626T1 (el)
HU (1) HUE053444T2 (el)
IL (4) IL274914B2 (el)
IN (1) IN2014CN03890A (el)
LT (2) LT2771357T (el)
MX (2) MX353134B (el)
PL (2) PL2771357T3 (el)
PT (2) PT3424947T (el)
RS (2) RS61455B1 (el)
RU (1) RU2661106C2 (el)
SG (2) SG11201401030WA (el)
SI (2) SI2771357T1 (el)
SM (2) SMT202100243T1 (el)
WO (1) WO2013063361A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2858978T3 (es) * 2011-10-28 2021-09-30 Regeneron Pharma Ratones con receptores de linfocitos T genéticamente modificados
CN103212064B (zh) * 2012-01-19 2016-02-17 中国科学院上海巴斯德研究所 磷酸化途径相关因子在调控调节性t细胞功能中的应用
KR101904508B1 (ko) 2012-04-25 2018-10-04 리제너론 파마슈티칼스 인코포레이티드 큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR20200136508A (ko) 2013-04-16 2020-12-07 리제너론 파마슈티칼스 인코포레이티드 랫트 게놈의 표적화된 변형
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
BR112016029650A2 (pt) * 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
PT3161128T (pt) 2014-06-26 2018-11-21 Regeneron Pharma Métodos e composições para modificações genéticas alvejadas e métodos de utilização
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
EP3521437B1 (en) 2014-11-21 2025-01-15 Regeneron Pharmaceuticals, Inc. Methods for targeted genetic modification using paired guide rnas
PL3689140T3 (pl) * 2014-11-24 2022-09-05 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
SG11201704646YA (en) 2014-12-19 2017-07-28 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
CN107666828B (zh) * 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
EP3907285A1 (en) 2015-05-06 2021-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
JP6997708B2 (ja) * 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
WO2017177137A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
JP7254519B2 (ja) 2016-04-08 2023-04-10 イムノコア リミテッド Ｔ細胞レセプター
RS66700B1 (sr) * 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CA3067226A1 (en) * 2017-06-16 2018-12-20 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN112585276A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
SG11202101789SA (en) * 2018-07-26 2021-03-30 Univ Kyoto Method for generating cells into which an exogenous antigen receptor is introduced
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3154287A1 (en) * 2019-09-12 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
US20230124640A1 (en) * 2020-03-27 2023-04-20 2Seventy Bio, Inc. T cell receptors
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
US20240114883A1 (en) * 2022-08-12 2024-04-11 Ingenious Targeting Laboratories Genetically modified non-human having humanized gamma and delta TCR variable genes
EP4573117A1 (en) 2022-08-18 2025-06-25 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
KR20250077529A (ko) * 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
GB202405657D0 (en) 2024-04-22 2024-06-05 T Therapeutics Ltd T cell receptor identification and provision
GB2640828A (en) 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
CA2246333A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
US6320306B1 (en) * 1996-08-05 2001-11-20 Samsung Display Devices Co., Ltd. Shadow mask with porous insulating layer and heavy metal layer
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002047474A1 (en) * 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
ES2389251T3 (es) 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US7329731B2 (en) 2001-08-31 2008-02-12 Medigene Limited Soluble T cell receptor
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
US7741077B2 (en) 2001-12-22 2010-06-22 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
DE60106469T2 (de) 2001-12-22 2005-10-13 4-Antbody AG Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
AU2003279820A1 (en) * 2002-10-30 2004-06-07 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
ES2382777T3 (es) * 2006-05-03 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Receptor de células T quimérico y materiales relacionados y métodos de uso
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
US9388425B2 (en) 2006-10-20 2016-07-12 Trustees Of Boston University Tunable genetic switch for regulating gene expression
JP2008159109A (ja) 2006-12-21 2008-07-10 Matsushita Electric Ind Co Ltd データ転送装置
ES2665068T3 (es) 2008-03-07 2018-04-24 Regeneron Pharmaceuticals, Inc. Ratones derivados de células ES a partir de inyección de un embrión hospedador diploide
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
NO2792236T3 (el) * 2009-07-08 2018-04-14
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CN105950654B (zh) 2010-11-27 2020-03-20 朱坚 一种人源化的转基因动物
ES2858978T3 (es) * 2011-10-28 2021-09-30 Regeneron Pharma Ratones con receptores de linfocitos T genéticamente modificados
CN107666828B (zh) 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答

Also Published As

Publication number Publication date
CN107858333B (zh) 2022-05-27
IL315445A (en) 2024-11-01
EP3424947A1 (en) 2019-01-09
JP6254528B2 (ja) 2017-12-27
ES2858978T3 (es) 2021-09-30
PL3424947T3 (pl) 2021-06-14
HK1198171A1 (en) 2015-03-13
SI2771357T1 (sl) 2018-11-30
EP2771357A1 (en) 2014-09-03
DK2771357T3 (en) 2018-10-29
AU2016202512A1 (en) 2016-05-12
CN107858333A (zh) 2018-03-30
KR102542272B1 (ko) 2023-06-13
HRP20210256T1 (hr) 2021-04-02
AU2012327204A1 (en) 2013-05-23
JP2023024744A (ja) 2023-02-16
ES2691475T3 (es) 2018-11-27
AU2021203192A1 (en) 2021-06-10
MX379517B (es) 2025-03-10
AU2018204700B2 (en) 2021-04-01
IL305550A (en) 2023-10-01
IL274914B1 (en) 2023-10-01
PL2771357T3 (pl) 2018-12-31
CN107858332A (zh) 2018-03-30
NZ623147A (en) 2016-03-31
SI3424947T1 (sl) 2021-04-30
HUE053444T2 (hu) 2021-06-28
LT2771357T (lt) 2018-10-25
US20220386575A1 (en) 2022-12-08
AU2016202512C1 (en) 2018-10-11
LT3424947T (lt) 2021-03-10
SMT201800553T1 (it) 2018-11-09
KR20190037354A (ko) 2019-04-05
JP2018007696A (ja) 2018-01-18
AU2024204645A1 (en) 2024-08-01
JP7656580B2 (ja) 2025-04-03
BR112014009203B1 (pt) 2023-02-28
AU2016202512B2 (en) 2018-03-29
AU2012327204B2 (en) 2016-01-21
IL274914A (en) 2020-07-30
JP6706311B2 (ja) 2020-06-03
CA2853707A1 (en) 2013-05-02
KR20220066197A (ko) 2022-05-23
US20210051930A1 (en) 2021-02-25
HRP20181626T1 (hr) 2018-12-14
AU2021203192B2 (en) 2024-04-11
CN104011071B (zh) 2017-11-07
MX2014004894A (es) 2014-09-12
IL232098A0 (en) 2014-05-28
JP2019033770A (ja) 2019-03-07
IL305550B1 (en) 2024-10-01
CN114891798B (zh) 2025-12-02
EP3795587A1 (en) 2021-03-24
IL305550B2 (en) 2025-02-01
CN104011071A (zh) 2014-08-27
US11528895B2 (en) 2022-12-20
AU2018204700C1 (en) 2021-10-14
JP2014532413A (ja) 2014-12-08
KR102397961B1 (ko) 2022-05-13
KR20140077219A (ko) 2014-06-23
RS57893B1 (sr) 2019-01-31
US20160021856A1 (en) 2016-01-28
JP2024019646A (ja) 2024-02-09
CY1120945T1 (el) 2019-12-11
KR20210133325A (ko) 2021-11-05
KR20200102001A (ko) 2020-08-28
CN114891797A (zh) 2022-08-12
RS61455B1 (sr) 2021-03-31
SG11201401030WA (en) 2014-04-28
BR112014009203A2 (pt) 2020-10-27
MX353134B (es) 2017-12-20
US9113616B2 (en) 2015-08-25
KR102321909B1 (ko) 2021-11-05
IL274914B2 (en) 2024-02-01
RU2661106C2 (ru) 2018-07-11
EP2771357B1 (en) 2018-07-18
KR101964776B1 (ko) 2019-04-04
PT3424947T (pt) 2021-03-01
EP3424947B1 (en) 2020-11-25
SG10201914043XA (en) 2020-03-30
JP7305840B2 (ja) 2023-07-10
PT2771357T (pt) 2018-11-09
CN114891798A (zh) 2022-08-12
IL232098B (en) 2020-06-30
AU2018204700A1 (en) 2018-07-19
JP2020146045A (ja) 2020-09-17
DK3424947T3 (da) 2021-02-22
KR102148387B1 (ko) 2020-08-26
JP6532924B2 (ja) 2019-06-19
WO2013063361A1 (en) 2013-05-02
RU2014121160A (ru) 2015-12-10
US20130109053A1 (en) 2013-05-02
SMT202100243T1 (it) 2021-05-07
JP2022093637A (ja) 2022-06-23
IN2014CN03890A (el) 2015-10-16

Similar Documents

Publication Publication Date Title
CY1123831T1 (el) Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων
CY1121869T1 (el) Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
CY1122700T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (μηc) ii
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1124627T1 (el) Στοχευμενη τροποποιηση γονιδιωματος αρουραιου
CY1121657T1 (el) Μεθοδοι και συνθεσεις για κατευθυνομενη απο rna τροποποιηση dna στοχου και για κατευθυνομενη απο rna ρυθμιση της μεταγραφης
CY1121738T1 (el) Μεθοδοι και συνθεσεις για στοχευμενη γενετικη τροποποιηση χρησιμοποιωντας συζευγμενα rna-οδηγους
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CY1120808T1 (el) Μεθοδοι και συνθεσεις για στοχευμενες γενετικες τροποποιησεις και μεθοδοι χρησης
CY1122179T1 (el) Μεθοδοι και συνθεσεις για την παραγωγη ή την διατηρηση πολυδυναμων κυτταρων
CY1122636T1 (el) Συνθεσεις για τη συνδεση στοιχειων με δακτυλους ψευδαργυρου
IL264271A (en) Methods of generating natural killer cells
CY1121223T1 (el) Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
BR112013018311A2 (pt) sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201391234A1 (ru) Генетически модифицированные животные и способы их получения
MX2022009653A (es) Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
UY34014A (es) Genes sintéticos para expresar proteínas en células de maíz, construcciones, plantas transgénicas, métodos para controlar pestes y composiciones
BR112017010793A2 (pt) animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
SG10201902811TA (en) High efficiency, high throughput generation of genetically modified mammals by electroporation
MX2017009272A (es) Anticuerpos que penetran en células.
BR112016011003A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
MY198884A (en) Lincrna-deficient non-human animals